The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 21 | — | 20.1x | Below average | |
Growth | 87 | 96.0% | 5.6% | Above average | |
Quality | 38 | -520.4% | 7.6% | Near average | |
Safety | 60 | -5.8x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Travere Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Travere Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Travere Therapeutics stock has witnessed a positive shift in analyst outlooks over the past 30 days, with the average price target rising by 10.04% to reach $56.67, compared to $51.5 previously. This increase occurred while the number of analysts remained steady (4 analysts), indicating an upward reassessment by existing institutions rather than just the entry of new opinions, with the current price ($45.2) remaining below the lowest price target ($49), reflecting optimism regarding a price growth gap.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.